As expected, the European Commission approves a subcutaneous fixed-dose formulation of Johnson & Johnson’s (JNJ -1.1%) Darzalex (daratumumab) for the treatment of multiple myeloma.
In April, the advisory group CHMP adopted a positive opinion backing approval.
https://seekingalpha.com/news/3580469-subcutaneous-formulation-of-j-and-js-darzalex-okd-in-europe
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.